Triple negative (TNBC) metastatic breast cancer is a heterogeneous disease, chemotherapy remains the mainstay of treatment, however, new treatments based on identifying molecular subtypes, stratifying TNBC based on gene expression assays with subsequent specific targeted therapy is an area of intense clinical research. In this post, I will review our current standard clinical practice and explore ongoing and future clinical directions.
Metastatic TNBC is very heterogenous, and while Basal type is most common, it only account for nearly 80% of all cases.
Continue reading “Triple Negative Metastatic Breast Cancer”
Pregnancy-associated breast cancer (PABC) is relatively rare. PABC is defined as breast cancer occurring during pregnancy, first postpartum year, or anytime during lactation. It is estimated to occur in 1 every 3000 pregnancies. On the other hand, it is the most common cancer during pregnancy, the incidence of PABC is expected to rise in developed countries, while historically PABC was always thought to have poor prognosis this is not universally true, it continues to represent a special challenge for early diagnosis and treatment options.
Continue reading “Pregnancy-Associated Breast Cancer”